<DOC>
	<DOCNO>NCT01360866</DOCNO>
	<brief_summary>To assess long-term safety tolerability oral OPC-34712 ( brexpiprazole ) , give addition FDA approve antidepressant ( ADT ) treatment adult Major Depressive Disorder ( MDD )</brief_summary>
	<brief_title>Safety Tolerability Oral OPC-34712 Adjunctive Therapy Adults With Major Depressive Disorder ( Orion Trial )</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Mood Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<criteria>Male Female outpatient 1865 year age Eligible subject Trials 33110227 , 33110228 33112282 : Subjects complete participation Doubleblind Randomization Phase ( i.e . Week 14 visit ) Trial 33110227 , Trial 33110228 , Trial 33112282 Subjects meet criterion response , meet criterion remission Week 14 either trial Eligible subject Phase 3 , Doubleblind , Brexpiprazole MDD trial : â€¢ Subjects complete last scheduled visit prior Doubleblind Randomized Phase 3 trial . Females breastfeed and/or positive pregnancy test result prior receive OPC34712 . Subjects major protocol violation course participation Doubleblind Randomization Phase</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>OPC-34712</keyword>
	<keyword>brexpiprazole</keyword>
	<keyword>Major Depressive Disorder</keyword>
	<keyword>Adjunctive Treatment</keyword>
</DOC>